Cell>Point is a biotech company that develops and commercializes molecular imaging and targeted therapeutics. It is engaged in the field of theranostic nuclear medicine through chelation technologies focused on cancer, cardiovascular, neuroendocrine, diabetes, and ischemia-based diseases. The company offers Oncardia, ethylenedicysteine-glucosamine that can be radiolabeled or complexed with cold metals to create a range of nuclear imaging and therapeutic products. Oncardia’s mechanism allows it to target the diseased cell and then deliver its radionuclide or cold metal into the cell nucleus.